Rebecca Aul
Nurse Practitioner · Phillipsburg, NJNPI 1306385018
Payments from drug & device makers
Across 147 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$480
- Sanofi$299
- Takeda Pharmaceuticals U.S.A., Inc.$201
- CSL Behring$161
- Amgen$152
- plus $819 from 18 others
What the payments were for
- Food & beverage$3,47898%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 53 | $1,435 |
| GSK | 23 | $480 |
| Sanofi | 13 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $201 |
| CSL Behring | 7 | $161 |
| Amgen | 6 | $152 |
| Biocryst US Sales Co., LLC | 4 | $105 |
| Boehringer Ingelheim | 4 | $95 |
| Genentech USA, Inc. | 3 | $92 |
| Mylan Specialty L.p. | 3 | $72 |
| Optinose US, Inc. | 4 | $67 |
| Pfizer | 3 | $59 |
| Kaleo, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Pharming Healthcare, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Novartis | 2 | $33 |
| Grifols USA, LLC | 1 | $24 |
| LEO Pharma Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Medline Industries LP | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,548 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 347 | $288,805 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 122 | $91,256 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $62,692 |
| Breo ElliptaFluticasone/Vilanterol | 128 | $62,530 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $42,798 |
| EliquisApixaban | 62 | $40,325 |
| Spiriva RespimatTiotropium Bromide | 50 | $35,390 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $19,079 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $16,639 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 384 | $11,218 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,089 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,622 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $7,767 |
| Arnuity ElliptaFluticasone Furoate | 23 | $7,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $480 | $440,496641 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,435 | $103,179159 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $95 | $86,810138 claims |
| PfizerEliquis | $59 | $40,32562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Phillipsburg
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Olufunmilayo IloriUnion$133K
- Janice BeitzHaddon Heights$75K
- Adewale AdefowojuUnion$70K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.